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Available online 11 November 2015Chronic lymphocytic leukemia (CLL) is the most common adult leukemia. While therapeutic antibodies show
clinical activity in CLL patients, resistance inevitably develops resulting in treatment failure. Identifying mecha-
nisms of antibody resistance andmethods to reduce resistancewould be valuable inmanaging CLL.Monocyte de-
rived cells (MDCs), also known as nurse like cells (NLCs) in CLL [1,2], are known to be crucial components of the
CLL microenvironment network and following “maturation” in in vitro culture systems are able to provide sup-
port for the survival of the malignant B cells from CLL patients. In addition to their protective role, MDCs are
key effector cells inmediating responses to therapeutic antibody therapies [3]. We have determined that macro-
phages from patients with early stable CLL are able to elicit superior cytotoxic response to therapeutic antibodies
thanmacrophages derived from patients with progressive CLL. We have exploited this unique ﬁnding to gain in-
sight into antibody resistance. Thus,we have proﬁledmonocytes on day 0 andMDCs on day 7 fromantibody sen-
sitive and antibody resistant CLL patients (GEO accession number GEO: GSE71409). We show that there are no
signiﬁcant differences in transcriptomes from themonocytes or MDCs derived from sensitive or resistant patient
samples. However, we show that MDCs acquire an M2-like macrophage transcriptomic signature following
7 days culture regardless of whether they were derived from sensitive or resistant patient samples.
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. This is an open access article under1. Direct link to deposited data
Deposited data can be found here: http://www.ncbi.nlm.nih.gov/
geo/query/acc.cgi?acc=GSE71409
2. Data
Whole genome transcriptomics data from CD14 positive monocytes
isolated from CLL patient peripheral blood mononuclear cells (PBMCs)
for four patients and monocyte derived cells from CLL PBMCs cultured
for seven days for seven patients.
3. Experimental design, materials and methods
3.1. Patient samples and cell puriﬁcation
Peripheral blood fromCLL patientswas collected after informed con-
sent according to protocols approved by the PrincessAlexandraHospital
(PAH) Human Research Ethics Committee. Patient characteristics are
outlined in Table 1. PBMCs were isolated by density-gradient cen-
trifugation over Histopaque-1077 and red blood cells lysed usingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient clinical features.
Patient code Age Sex CD38 Zap 70 IgVH status FISH
CLL261 40 M Negative Positive Unmutated 13q deletion & 17p deletion
CLL292 77 M Positive Positive ND 11q deletion & 13q deletion
CLL315 75 F Negative Positive Mutated Trisomy 12
CLL338 69 F Negative Positive Mutated ND
CLL395 70 F Negative Positive ND Normal karyotype
CLL398 59 F Negative Negative Mutated 13q deletion
CLL399 41 M Positive Positive Mutated 17p deletion + monosomy 12
CLL404 88 M Positive Positive Unmutated 13q deletion
CLL409 72 M Negative Positive Mutated 13q deletion
CLL414 67 M Positive Positive Unmutated 17p deletion & 13q deletion
5M. Burgess et al. / Genomics Data 7 (2016) 4–6ammonium chloride. To determine antibody sensitivity, CLL PBMCs
were cultured in RPMI +10% fetal calf serum in the presence of
LEAF Puriﬁed anti-human CD62L antibody (DREG56; 0.1 μg/ml;
Biolegend) and CLL cell survival examined after seven days using trypan
blue exclusion [4]. CLL patients' responses were classiﬁed as sensitive
if survival ≤40% or resistant if survival ≥70% of untreated cultures
(Fig. 1A).
For day 0 samples, monocytes were isolated from CLL PBMCs using
MACS cell separation andCD14MicroBeads according tomanufacturer's
instructions (Miltenyi Biotec). Purity of samples was examined by ﬂow
cytometry and all samples ≥85% based on CD14 positivity. For day 7
monocyte-derived cells (MDCs), CLL PBMCs were maintained in RPMI
10% FCS for seven days to allowmaturation of MDCs andMDCs isolated
after removal of non-adherent cells. Representative images showing
MDC morphology from an antibody sensitive and antibody resistant
CLL patient is shown in Fig. 1B. CD14 positive monocytes from 2 sensi-
tive and 2 resistant patients and MDCs from 4 sensitive and 3 resistant
CLL patients are used in this study.Fig. 1.Differential sensitivity to CD62L antibody in vitro. (A) CLL PBMCswere cultured in the pre
7 days using trypan blue exclusion. CLL cell survival was normalized to untreated CLL PBMCs su
gentle agitation and MDCs were visualized by Giemsa staining (magniﬁcation = 20×). A repre3.2. Gene expression analysis
Total RNA from monocytes and MDCs was extracted with Bioline
Isolate II RNA Micro kit in accordance with the prescribed protocol
provided with the kit (Bioline). The integrity of the isolated RNA was
determined using Agilent RNA 6000 Pico kit (Agilent Technologies) on
an Agilent Bioanalyzer. Microarray proﬁling was performed using
Illumina HumanHT-12 v4 Expression BeadChips (Illumina) as per the
manufacturer's protocol. Probe intensities have been background
corrected using negative control probes and quantile normalized using
the neqc [5] function of the limma [6] package.
Microarray data have been uploaded to Gene Expression Omnibus
under the reference: GSE71409. The original CEL ﬁles from GEO acces-
sion GSE5099 [7,8] were downloaded. These contain gene expression
data for freshly isolated monocytes at day 0, macrophages at day 3
and day 7, Interferon Gamma and LPS treated macrophages and IL-4
treated macrophages. These experiments were performed on the
Affymetrix Human Genome U133A Array. Arrays from GSE5099 andsence of anti-human CD62L antibody (DREG56; 0.1 μg/ml) and cell survival examined after
rvival. (B) CLL PBMCswere cultured for 7 days before non-adherent cells were removed by
sentative image from one sensitive and one resistant patient is shown.
Fig. 2. CLLMDCs display characteristics similar toM2macrophages. Microarray data frommonocytes on day 0 andMDCs on day 7 from sensitive and resistant patients were compared to
those fromGEO accession GSE5099. Datasets weremerged on common genes and the program ‘virtualArray’was applied to remove platform speciﬁc batch effects using an unsupervised
empirical Bayes algorithm. (A)multidimensional scalingplot and (B) heatmap of the top 500geneswith themost variable expression. Bothﬁgures show a similar pattern: the day 0mono-
cytes of the current study are most similar to the day 0 monocytes obtained byMartinez et al. (ref. 7) while the day 7 macrophages of the current study cluster close to the day 7 macro-
phages andM2macrophages ofMartinez et al. (ref. 7).M1 cells have a gene expression proﬁle that is dissimilar to any other cell type either in the previously published study or the current
study.
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speciﬁc tools: the Affymetrix arrays were normalized using the RMA al-
gorithm [9,10] and the Illumina arrays were quantile normalized after
applying the VST algorithm [11,12]. Large platform speciﬁc batch effects
were observed between the two datasets, so an unsupervised empirical
Bayes method was used to remove these batch effects after as imple-
mented in the ‘virtualArray’ package [13]. The two datasets were
merged on common genes after multiple probes that mapped to the
same gene were collapsed by taking the median expression value per
sample. Genes that had no expression detected in any sample across
both studies (as indicated with a detection p-value b 0.01) were re-
moved from the data.
4. Conclusion
MDCs isolated from PBMCs of CLL patients are frequently referred to
as nurse like cells and are known to promote the survival of malignant
B cells in culture and to mediate responses to therapeutic antibodies
[1–3]. We have compared the transcriptomic proﬁles of MDCs that are
sensitive to, or resistant to, therapeutic antibodies.
Transcriptomic proﬁling of freshly isolatedmonocytes and 7 day ad-
herentMDCs from 4 freshly isolated and 7 adherent (7 day) patient cul-
tures failed to ﬁnd statistically signiﬁcant differentially expressed
transcripts that discriminate between MDCs derived from sensitive vs
resistant patients. However, after normalization and correction for
platform-speciﬁc batch effects, we were able to compare our dataset
to that of a previously published dataset of MDCs cultured for 0, 3 or
7 days [7]. Clustering of our transcript data and that of Martinez et al.
[7] reveals marked similarities between the two datasets (Fig. 2A & B).
The day 0 monocytes of both studies cluster together and are more
similar to one another than any other cell type. Moreover, while the
day 7 adherent MDCs from the current study, form their own distinct
cluster they share similarities with the day 3, day 7 and M2 macro-
phages of Martinez, et al. [7]. These data conﬁrm that following 7 daysculture our MDCs are enriched for macrophages/NLCs which display
an M2-like transcript proﬁle.
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